Barry D. Quart
2017
In 2017, Barry D. Quart earned a total compensation of $4.2M as President and Chief Executive Officer at Heron Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $246,958 |
|---|---|
| Option Awards | $3,391,524 |
| Salary | $596,518 |
| Other | $8,100 |
| Total | $4,243,100 |
Quart received $3.4M in option awards, accounting for 80% of the total pay in 2017.
Quart also received $247K in non-equity incentive plan, $596.5K in salary and $8.1K in other compensation.
Rankings
In 2017, Barry D. Quart's compensation ranked 2,374th out of 14,666 executives tracked by ExecPay. In other words, Quart earned more than 83.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,374 out of 14,666 | 84th |
Division Manufacturing | 833 out of 5,772 | 86th |
Major group Chemicals And Allied Products | 220 out of 2,075 | 89th |
Industry group Drugs | 167 out of 1,731 | 90th |
Industry Pharmaceutical Preparations | 132 out of 1,333 | 90th |
Source: SEC filing on April 23, 2020.
Quart's colleagues
We found three more compensation records of executives who worked with Barry D. Quart at Heron Therapeutics in 2017.
News
Heron Therapeutics CEO Craig Collard receives $11M in 2023
April 29, 2024
Heron Therapeutics Executive Vice President, Drug Development Kimberly Manhard's 2022 pay falls 22% to $1.4M
May 1, 2023
Heron Therapeutics CEO Barry Quart's 2021 pay rises 2% to $5.4M
April 25, 2022
Heron Therapeutics CEO Barry Quart's 2020 pay slips 9% to $5.3M
April 22, 2021
Heron Therapeutics CEO Barry Quart's 2019 pay slips 2% to $5.9M
April 23, 2020